Access DB# 55818

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner # :_____ Date: _____
Art Unit: _____ Phone Number 30_____ Serial Number: _____
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:	NA Sequence (#)		STN	
Searcher Phone #: 44198	AA Sequence (#)	✓	Dialog	
Searcher Location:	Structure (#)		Questel/Orbit	
Date Searcher Picked Up: 3/15/03	Bibliographic		Dr.Link	
Date Completed: 3/15/03	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	Fulltext		Sequence Systems	✓
Clerical Prep Time: 15	Patent Family		WWW/Internet	
Online Time: 40	Other		Other (specify)	

PTO-1590 (8-01)

```
egin 5,73,155,399
       03may03 07:31:33 User208760 Session D2298.2
            $0.00    0.071 DialUnits File410
     $0.00  Estimated cost File410
     $0.03  TELNET
     $0.03  Estimated cost this search
     $0.35  Estimated total session cost   0.161 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2003/Apr W4
         (c) 2003 BIOSIS
*File   5: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File  73:EMBASE  1974-2003/Apr W4
         (c) 2003 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 155:MEDLINE(R)  1966-2003/Apr W4
         (c) format only 2003 The Dialog Corp.
*File 155: Medline has been reloaded and accession numbers have
changed.  Please see HELP NEWS 155.
  File 399:CA SEARCH(R)  1967-2003/UD=13818
         (c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? s (cd40L or cd40(w)ligand) and (treat? or therap? or prevent? or suppress? or
block? or inhibit?)(20n)(cancer? or tumor? or tumour?)
Processing
Processing
Processing
Processing
Processing
Processing
           4407  CD40L
          17518  CD40
         342860  LIGAND
           7980  CD40(W)LIGAND
        6000244  TREAT?
        5560564  THERAP?
        1926273  PREVENT?
         746765  SUPPRESS?
        1172882  BLOCK?
        3709658  INHIBIT?
        1990055  CANCER?
        2021890  TUMOR?
         268769  TUMOUR?
        1025598  (((((TREAT? OR THERAP?) OR PREVENT?) OR SUPPRESS?) OR
                 BLOCK?) OR INHIBIT?)(20N)((CANCER? OR TUMOR?) OR TUMOUR?)
     S1     745  (CD40L OR CD40(W)LIGAND) AND (TREAT? OR THERAP? OR
                 PREVENT? OR SUPPRESS? OR BLOCK? OR INHIBIT?)(20N)(CANCER?
                 OR TUMOR? OR TUMOUR?)
? s s1 and photodynamic
           745  S1
         26253  PHOTODYNAMIC
     S2      1  S1 AND PHOTODYNAMIC
? t s2/3/all

 2/3/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
```

135339226 CA: 135(24)339226q PATENT
Method for treatment of tumors using photodynamic therapy
INVENTOR(AUTHOR): Fanslow, William C., III; Thomas, Elaine K.
LOCATION: USA
ASSIGNEE: Immunex Corporation
PATENT: PCT International ; WO 200180888 A2 DATE: 20011101
APPLICATION: WO 2001US13616 (20010425) *US PV199545 (20000425)
PAGES: 24 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG ; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

```
? s s1 and cd30?
             745  S1
            5966  CD30?
      S3      33  S1 AND CD30?
? rd s3
...completed examining records
      S4      25  RD S3 (unique items)
? t s4/3/all
```

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13501169 BIOSIS NO.: 200200129990
Depletion of normal B-lymphocytes by rituximab therapy alters serum cytokine levels, resolves B-symptoms and induces clinical remissions in patients with relapsed classical Hodgkin's disease (HD).
AUTHOR: Younes Anas(a); Romaguera Jorge(a); Hagemeister Frederick(a); Mclaughlin Peter(a); Rodriguez Maria Alma(a); Fiumara Paolo(a); Goy Andre (a); Jeha Sima; Manning John; Medeiros L Jeffrey; Martinez Rudy F(a); Cabanillas Fernando(a)
AUTHOR ADDRESS: (a)Lymphoma/Myeloma, M.D.Anderson Cancer Center (MDACC), Houston, TX**USA
JOURNAL: Blood 98 (11 Part 1):p132a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13112983 BIOSIS NO.: 200100320132
A pilot study of rituximab in patients with relapsed Hodgkin's disease of classical type.
AUTHOR: Younes A(a); Romaguera J(a); Hagemeister F(a); Rodriguez M(a); McLaughlin P(a); Medeiros J(a); Cabanillas F(a)
AUTHOR ADDRESS: (a)U.T. M.D. Anderson Cancer Center, Houston, TX**USA
JOURNAL: Blood 96 (11 Part 1):p733a November 16, 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000
SPONSOR: American Society of Hematology
ISSN: 0006-4971

RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13057538 BIOSIS NO.: 200100264687
Chronic lymphocytic leukemia B cells impair immunoglobulin class switching by inducing **CD30**+ suppressor T cells.
AUTHOR: Cerutti Andrea(a); Kim Edmund C(a); Zan Hong(a); Schaffer Andras(a); Casali Paolo(a)
AUTHOR ADDRESS: (a)Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10021**USA
JOURNAL: FASEB Journal 15 (5):pA1202 March 8, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13033028 BIOSIS NO.: 200100240177
Thiols decrease cytokine levels and down-regulate the expression of **CD30** on human allergen-specific T helper (Th) 0 and Th2 cells.
AUTHOR: Bengtsson A(a); Lundberg M; Avila-Carino J; Jacobsson G; Holmgren A; Scheynius A
AUTHOR ADDRESS: (a)Deparment of Medicine, Unit of Clinical Allergy Research, Karolinska Hospital L2: 04, 171 76, Stockholm: asa.bengtsson@mb.ks.se**Sweden
JOURNAL: Clinical and Experimental Immunology 123 (3):p350-360 March, 2001
MEDIUM: print
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12615531 BIOSIS NO.: 200000369033
TTRAP, a novel protein that associates with CD40, **tumor** necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that **inhibits** nuclear factor-kappaB activation.
AUTHOR: Pype Stefan; Declercq Wim; Ibrahimi Abdelilah; Michiels Christine; Van Rietschoten Johanna G I; Dewulf Nathalie; de Boer Mark; Vandenabeele Peter; Huylebroeck Danny(a); Remacle Jacques E
AUTHOR ADDRESS: (a)Department of Cell Growth, Differentiation and Development, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Herestraat 49, Campus Gasthuisberg, B-3000, Leuven **Belgium
JOURNAL: Journal of Biological Chemistry 275 (24):p18586-18593 June 16,

2000
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11525042 BIOSIS NO.: 199800306374
Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (**CD40 ligand**) costimulatory molecules in tumor cells.
AUTHOR: Couderc Bettina; Zitvogel Laurence; Douin-Echinard Victorine; Djennane Leila; Tahara Hideaki; Favre Gilles; Lotze Michael T; Robbins Paul D(a)
AUTHOR ADDRESS: (a)Dep. Mol. Genet. and Biochem., W1246 Biomed. Sci. Tower, Univ. Pittsburgh Sch. Med., Pittsburgh,**USA
JOURNAL: Cancer Gene Therapy 5 (3):p163-175 May-June, 1998
ISSN: 0929-1903
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11226541 BIOSIS NO.: 199800007873
CD30 ligand in lymphoma patients with **CD30**!+ tumors.
AUTHOR: Younes Anas(a); Consoli Ugo; Snell Virginia; Clodi Katharina; Kliche Kay-Oliver; Palmer J Lynn; Gruss Hans J; Armitage Richard; Thomas Elaine K; Cabanillas Fernando; Andreeff Michael
AUTHOR ADDRESS: (a)Dep. Hematol., Section Lymphoma, Univ. Texas M.D. Anderson Cancer Cent., 1515 Holcombe Blvd., Ho**USA
JOURNAL: Journal of Clinical Oncology 15 (11):p3355-3362 Nov., 1997
ISSN: 0732-183X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11933828 EMBASE No: 2003044479
T-cell costimulatory pathways relevant to transplant rejection and tolerance
Wells A.D.
Dr. A.D. Wells, Dept. of Pathology/Laboratory Med., Children's Hospital of Philadelphia, University of Pennsylvania, 3516 Civic Center Blvd., Philadelphia, PA 19104-4318 United States
Transplantation Reviews (TRANSPL. REV.) (United States) 2002, 16/4 (205-219)
ISSN: 0955-470X
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 214

4/3/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11449616 EMBASE No: 2002021386
Expression of **CD40 ligand** (CD154) in B and T lymphocytes of Hodgkin disease: Potential therapeutic significance
Clodi K.; Asgari Z.; Younes M.; Palmer J.L.; Cabanillas F.; Carbone A.; Andreeff M.; Younes A.
Dr. A. Younes, Department of Lymphoma/Myeloma, University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 United States
AUTHOR EMAIL: ayounes@notes.mdacc.tmc.edu
Cancer (CANCER) (United States) 01 JAN 2002, 94/1 (1-5)
CODEN: CANCA ISSN: 0008-543X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 20

4/3/10 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

07928709 EMBASE No: 1999402580
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells
Kashii Y.; Giorda R.; Herberman R.B.; Whiteside T.L.; Vujanovic N.L.
Dr. N.L. Vujanovic, University of Pittsburgh, Cancer Institute, Biomedical Science Tower W1045, 211 Lothrop Street, Pittsburgh, PA 15213 United States
AUTHOR EMAIL: vujanovicn1@msx.upmc.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 1999, 163/10 (5358-5366)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 37

4/3/11 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

07068504 EMBASE No: 1997350367
CD30 ligand in lymphoma patients with **CD30sup** + tumors
Younes A.; Consoli U.; Snell V.; Clodi K.; Kliche K.-O.; Palmer J.L.; Gross H.J.; Armitage R.; Thomas E.K.; Cabanillas F.; Andreelf M.
Dr. A. Younes, Department of Hematology, Section of Lymphoma, Texas M.D. Anderson Can. Ctr. Univ., 1515 Holcombe Blvd, Houston, TX 77030 United States
AUTHOR EMAIL: ayounes@notes.mdacc.tmc.edu
Journal of Clinical Oncology (J. CLIN. ONCOL.) (United States) 1997, 15/11 (3355-3362)
CODEN: JCOND ISSN: 0732-183X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 24

4/3/12 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138220374 CA: 138(15)220374h PATENT
Anti-CD3 and anti-T cell costimulatory molecule antibodies for producing human CD4+ Th1 cells for treating infection and cancer
INVENTOR(AUTHOR): Fowler, Daniel H.; Hou, Jeanne; Jung, Unsu; Gress, Ronald E.; Levine, Bruce; June, Carl
LOCATION: USA
ASSIGNEE: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services; The Trustees of the University of Pennsylvania
PATENT: PCT International ; WO 200320904 A2 DATE: 20030313
APPLICATION: WO 2002US27824 (20020829) *US PV316854 (20010831)
PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS ; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/13 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138088660 CA: 138(7)88660s PATENT
Monclonal anti-CD3 antibodies for producing human CD4+ Th2 cells to treat graft versus host disease, tumors, and autoimmune disorders
INVENTOR(AUTHOR): Fowler, Daniel H.; Hou, Jeanne; Jung, Unsu; Gress, Ronald E.; Bishop, Michael; Levine, Bruce; June, Carl
LOCATION: USA
ASSIGNEE: United States of America, Health and Human Services; The Trustees of the University of Pennsylvania
PATENT: PCT International ; WO 200304625 A1 DATE: 20030116
APPLICATION: WO 2002US20415 (20020626) *US PV302936 (20010702)
PAGES: 70 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-005/00A; C12N-005/02B; A61K-039/395B; C07K-016/00B DESIGNATED COUNTRIES: AE; AG; AL ; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW ; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/14 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

137365329 CA: 137(25)365329m PATENT
Recombinant trimerizing fusion proteins and their use in disease treatment
INVENTOR(AUTHOR): Tschopp, Juerg; Schneider, Pascal
LOCATION: Switz.
ASSIGNEE: Apotech Research & Development Ltd.
PATENT: PCT International ; WO 200290553 A2 DATE: 20021114
APPLICATION: WO 2002EP5103 (20020508) *DE 10122140 (20010508)
PAGES: 46 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: C12N-015/62A; C07K-014/47B; C07K-014/525B; C07K-019/00B; C12N-001/21B; C12N-005/10B;

A61K-038/17B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/15 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

137088489 CA: 137(7)88489x PATENT
Secreted Frizzled-related protein (sFRP) and protein motifs that interact with sFRP and therapeutic uses thereof
INVENTOR(AUTHOR): Rubin, Jeffrey S.; Uren, Aykut; Horwood, Nicole Joy; Gillespie, Matthew Todd; Kay, Brian K.; Weisblum, Bernard
LOCATION: USA
ASSIGNEE: The Government of the United States of America, Department of Health and Human Services; St. Vincent's Institute of Medical Research
PATENT: PCT International ; WO 200255547 A2 DATE: 20020718
APPLICATION: WO 2002US869 (20020110) *US PV260908 (20010110)
PAGES: 81 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/00A; C07K-007/08B; C07K-007/06B; C12N-015/11B; A61K-038/04B; A61P-019/08B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/16 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135348851 CA: 135(24)348851s PATENT
Albumin fusion proteins with therapeutic proteins for improved shelf-life
INVENTOR(AUTHOR): Rosen, Craig A.; Haseltine, William A.
LOCATION: USA
ASSIGNEE: Human Genome Sciences, Inc
PATENT: PCT International ; WO 200179444 A2 DATE: 20011025
APPLICATION: WO 2001US12013 (20010412) *US PV229358 (20000412) *US PV199384 (20000425) *US PV256931 (20001221)
PAGES: 606 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/17 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135339226 CA: 135(24)339226q PATENT
Method for treatment of tumors using photodynamic therapy
INVENTOR(AUTHOR): Fanslow, William C., III; Thomas, Elaine K.
LOCATION: USA
ASSIGNEE: Immunex Corporation
PATENT: PCT International ; WO 200180888 A2 DATE: 20011101
APPLICATION: WO 2001US13616 (20010425) *US PV199545 (20000425)
PAGES: 24 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/18 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

135104086 CA: 135(8)104086e PATENT
Multimerization domain-containing fusion proteins and use of fusion protein multimers for therapy and diagnosis
INVENTOR(AUTHOR): Tschopp, Juerg; Schneider, Pascal; Holler, Nils
LOCATION: Switz.
ASSIGNEE: Apotech Research and Development Ltd.
PATENT: PCT International ; WO 200149866 A1 DATE: 20010712
APPLICATION: WO 2000EP13032 (20001220) *DE 19963859 (19991230)
PAGES: 96 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: C12N-015/62A; C12N-015/11B; C07K-014/705B; A61K-038/17B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/19 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134290751 CA: 134(21)290751v PATENT
Recombinant single-chain receptor antagonist proteins and their use in treatment of inflammatory disorders
INVENTOR(AUTHOR): Halkier, Torben; Schambye, Hans Thalsgard; Okkels, Jens Sigurd; Andersen, Kim Vilbour; Nissen, Torben Lauesgaard; Soni, Bobby; Jeppesen, Claus Bekker; Van Den Hazel, Bart
LOCATION: Den.
ASSIGNEE: Maxygen Aps
PATENT: PCT International ; WO 200125277 A1 DATE: 20010412
APPLICATION: WO 2000DK563 (20001006) *DK 991438 (19991007) *DK 991855 (19991223) *DK 20001119 (20000720)
PAGES: 123 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/525A; A61K-038/22B; A61P-029/00B; C07K-019/00B; C07K-001/107B; C12N-015/62B; C07K-014/52B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG;

SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/20 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

134290399 CA: 134(21)290399m PATENT
Compositions and methods for tumor-targeted delivery of effector molecules
INVENTOR(AUTHOR): Bermudes, David G.; King, Ivan C.; Clairmont, Caroline A.; Lin, Stanley L.; Belcourt, Michael
LOCATION: USA
ASSIGNEE: Vion Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200125397 A2 DATE: 20010412
APPLICATION: WO 2000US23242 (20000824) *US PV157500 (19991004) *US PV157581 (19991004) *US PV157637 (19991004)
PAGES: 185 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG ; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

4/3/21 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133191263 CA: 133(14)191263k JOURNAL
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes
AUTHOR(S): Zambello, Renato; Trentin, Livio; Facco, Monica; Siviero, Marta; Galvan, Silvia; Piazza, Francesco; Perin, Alessandra; Agostini, Carlo; Semenzato, Gianpietro
LOCATION: Division of Hematology, Vicenza Hospital, Vicenza, Italy
JOURNAL: Blood DATE: 2000 VOLUME: 96 NUMBER: 2 PAGES: 647-654
CODEN: BLOOAW ISSN: 0006-4971 LANGUAGE: English PUBLISHER: American Society of Hematology

4/3/22 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133163045 CA: 133(12)163045x PATENT
Preparation of human effector T cells with CD86 on their surface and their therapeutic use
INVENTOR(AUTHOR): Jeannin, Pascale; Delneste, Yves; Vittori, Marc; Bonnefoy, Jean-Yves
LOCATION: Fr.
ASSIGNEE: Pierre Fabre Medicament
PATENT: PCT International ; WO 200046352 A1 DATE: 20000810
APPLICATION: WO 2000FR240 (20000202) *FR 991187 (19990202)
PAGES: 55 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C12N-005/08A; A61P-037/00B; A61K-035/14B; C12N-005/10B; C07K-014/52B; A61K-039/00B; G01N-033/50B DESIGNATED COUNTRIES: AU; BR; CA; CN; JP; MX; US; ZA
DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;

LU; MC; NL; PT; SE

4/3/23 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

133145450 CA: 133(11)145450w PATENT
M68: a soluble member of the tumor necrosis factor receptor family identified by gene discovery and its uses
INVENTOR(AUTHOR): Bai, Chang
LOCATION: USA
ASSIGNEE: Merck and Co., Inc.
PATENT: PCT International ; WO 200046247 A1 DATE: 20000810
APPLICATION: WO 2000US3037 (20000204) *US PV118902 (19990205) *US PV172754 (19991220)
PAGES: 86 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/47A; C07H-021/04B; C12N-015/62B; C12N-015/63B; C12N-005/22B; G01N-033/52B; G01N-033/53B; A61K-031/70B; A61K-038/17B DESIGNATED COUNTRIES: CA; JP; US
DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

4/3/24 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

129329705 CA: 129(25)329705g PATENT
Receptor protein and its use
INVENTOR(AUTHOR): Nishi, Kazunori; Shintani, Atsushi; Horiguchi, Takashi
LOCATION: Japan,
ASSIGNEE: Takeda Chemical Industries, Ltd.
PATENT: European Pat. Appl. ; EP 873998 A2 DATE: 19981028
APPLICATION: EP 98303190 (19980424) *JP 97109798 (19970425) *JP 97251867 (19970917)
PAGES: 65 pp. CODEN: EPXXDW LANGUAGE: English CLASS: C07K-014/705A; C07K-016/28B; C12N-015/12B DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO

4/3/25 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

129077575 CA: 129(7)77575f PATENT
Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
INVENTOR(AUTHOR): Kipps, Thomas J.; Sharma, Sanjai; Cantwell, Mark
LOCATION: USA
ASSIGNEE: University of California
PATENT: PCT International ; WO 9826061 A2 DATE: 19980618
APPLICATION: WO 97US22740 (19971208) *US 32145 (19961209) *US 982272 (19971201)
PAGES: 167 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/00A; A61K-048/00B DESIGNATED COUNTRIES: AT; AU; BR; CA; CH; CN; DE; DK; ES; FI; GB; IL; JP; KR; LU; MX; NO; NZ; PT; RU; SE; SG DESIGNATED REGIONAL: AT; BE ; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
? t s4/7/1-10

4/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13501169 BIOSIS NO.: 200200129990
Depletion of normal B-lymphocytes by rituximab therapy alters serum cytokine levels, resolves B-symptoms and induces clinical remissions in patients with relapsed classical Hodgkin's disease (HD).
AUTHOR: Younes Anas(a); Romaguera Jorge(a); Hagemeister Frederick(a); Mclaughlin Peter(a); Rodriguez Maria Alma(a); Fiumara Paolo(a); Goy Andre (a); Jeha Sima; Manning John; Medeiros L Jeffrey; Martinez Rudy F(a); Cabanillas Fernando(a)
AUTHOR ADDRESS: (a)Lymphoma/Myeloma, M.D.Anderson Cancer Center (MDACC), Houston, TX**USA
JOURNAL: Blood 98 (11 Part 1):p132a November 16, 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Although the malignant Hodgkin and Reed-Sternberg (H/RS) cells of HD are predominantly of B cell origin, only in 25%-30% of the cases they express CD20 antigen. However, infiltrating benign CD20-positive B cells in HD lymph nodes frequently express **CD30** ligand and **CD40 ligand** that can provide H/RS cells with survival signals, suggesting that B-cells of HD may play a role in the growth regulation of H/RS cells in vivo. With this background, we hypothesized that depletion of the CD20-positive normal B cells from HD lesions may deprive the H/RS cells from important survival factors and could lead to clinical responses. To test this hypothesis, we initiated a pilot study of single agent rituximab for the **treatment** of patients with relapsed classical HD. All patients received 6 weekly doses of 375 mg/m2 rituximab. **Tumor** response was determined at week 9 and every 3 months thereafter. Twenty-four patients were enrolled, of whom 22 patients are evaluable for treatment response. All patients had nodular sclerosis histology. Median number of prior treatment regimens was 4 (range 2 to 12), and 18 patients had prior bone marrow or stem cell tranplantation. Relapses involved extranodal sites in 12 patients. CD20 expression on H/RS was observed in 5 cases. Five (23%) patients achieved partial or complete remissions (2 expressed CD20 on H/RS cells), and 8 (36%) had stable disease. All responses were seen in patients whose disease did not involve extranodal sites and were irrespective of CD20 expression on H/RS cells. Seven patients had B symptoms prior to rituximab therapy, which resolved in 6 after therapy (3 had also had clinical esponses). Serum levels of IL-6, IL-10, IL-12, IL-13, and interferon-gamma were measured in 8 patients before and after rituximab therapy by ELISA. Rituximab therapy significantly decreased IL-6 levels in 2 patients who also achieved partial remissions. IL-10 levels decreased in 3 patients but did not correlate with clinical responses. None of the patients had detectable levels of serum IL-12, interferon-gamma, or IL-13. Our data suggest that depletion of normal B cells in patients with relapsed classical HD can alter cytokine levels, improve B-symptoms, and may result in clinical remissions esppecially in patients whose disease is limited to the lymph nodes. Based on these data we are currently combining rituximab with chemotherapy for the treatment of patients with classical HD to explore whether depletion of normal B cells from HD lesions may enhance the activity of chemotherapy.

4/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13112983 BIOSIS NO.: 200100320132
A pilot study of rituximab in patients with relapsed Hodgkin's disease of classical type.

AUTHOR: Younes A(a); Romaguera J(a); Hagemeister F(a); Rodriguez M(a); McLaughlin P(a); Medeiros J(a); Cabanillas F(a)
AUTHOR ADDRESS: (a)U.T. M.D. Anderson Cancer Center, Houston, TX**USA
JOURNAL: Blood 96 (11 Part 1):p733a November 16, 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000
SPONSOR: American Society of Hematology
ISSN: 0006-4971
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: We have previously reported that normal B lymphocytes in lymph nodes and peripheral blood of patients with Hodgkin's disease (HD) express **CD40 Ligand** (**CD40L**) and **CD30** Ligand (**CD30L**). Both ligands can activate NF-kappabeta and promote Reed-Sternberg (RS) cell survival. Therefore, we hypothesized that elimination of B lymphocytes from HD lesions may deprive the RS cells of important growth signals and may result in **tumor** regression. To examine this hypothesis, we **treated** patients with relapsed classic HD with 375 mg/m2 of rituximab IV every week for 6 consecutive weeks. Patients were eligible if they had relapsed classic HD, regardless of CD20 antigen expression on RS cells, and had at least two prior treatment regimens. Patients were excluded if they were pregnant women, had lymphocyte depletion or lymphocyte-predominant histology, were infected with HIV virus, or had CNS involvement by lymphoma. Objective tumor response was assessed after completion of six doses. Eighteen patients with nodular sclerosis histology are enrolled, of whom 15 have completed the planned therapy and are evaluable for response. CD20 antigen was expressed by the RS cells in 5 patients. Patient age ranged between 17 and 66 years and the number of prior treatment regimens ranged between 2 and 7 (median, 5 regimens). Thirteen patients had prior bone marrow transplantation. Seven patients had disease limited to lymph nodes and 8 had disease involving lymph nodes plus lungs and/or liver. Three patients (20%) had major responses (2 PRs and 1 CRu). All responding patients had disease limited to lymph nodes and the RS cells did not express CD20. Six additional patients had stable disease of whom 2 experienced resolution of B symptoms. We conclude that rituximab therapy, possibly by eliminating normal B lymphocytes from HD patients, can result in major clinical responses and symptom improvement.

4/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13057538 BIOSIS NO.: 200100264687
Chronic lymphocytic leukemia B cells impair immunoglobulin class switching by inducing **CD30**+ suppressor T cells.
AUTHOR: Cerutti Andrea(a); Kim Edmund C(a); Zan Hong(a); Schaffer Andras(a); Casali Paolo(a)
AUTHOR ADDRESS: (a)Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10021**USA
JOURNAL: FASEB Journal 15 (5):pA1202 March 8, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: B cell chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder associated with impaired Ig class switching from IgM to IgG and IgA, a defect that leads to recurrent infections. The pathogenesis of this immunodeficiency is poorly understood. Naive B cells undergo class switching upon engagement of CD40 by CD154 (**CD40 ligand**), a molecule expressed by T cells a few hours after activation by antigen. Four days later, T cells express **CD30**, a negative modulator of the immune response. We show here that leukemic CLL B cells rapidly up-regulate T cell **CD30** through a CD134 ligand (OX40 ligand) and IL-4-dependent mechanism. These **CD30**+ T cells **inhibit** class switch DNA recombination by engaging CD153 (**CD30** ligand), a molecule that interferes with the assembly of the CD40:**tumor** necrosis factor receptor associated factor (TRAF) complex in CD154-activated naive B cells. By showing that engagement of T cell **CD30** by CD153 on leukemic B cells down-regulates CD154, our findings suggest that, in CLL, dysregulated **CD30**:CD153 interaction impairs class switching by transmitting bidirectional CD40 and CD154-inhibitory signals.

4/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13033028 BIOSIS NO.: 200100240177
Thiols decrease cytokine levels and down-regulate the expression of **CD30** on human allergen-specific T helper (Th) 0 and Th2 cells.
AUTHOR: Bengtsson A(a); Lundberg M; Avila-Carino J; Jacobsson G; Holmgren A ; Scheynius A
AUTHOR ADDRESS: (a)Deparment of Medicine, Unit of Clinical Allergy Research, Karolinska Hospital L2: 04, 171 76, Stockholm: asa.bengtsson@mb.ks.se**Sweden
JOURNAL: Clinical and Experimental Immunology 123 (3):p350-360 March, 2001
MEDIUM: print
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The thiol antioxidant N-acetyl-L-cysteine (NAC), known as a precursor of glutathione (GSH), is used in AIDS **treatment** trials, as a chemoprotectant in **cancer** chemotherapy and in **treatment** of chronic bronchitis. In vitro, GSH and NAC are known to enhance T cell proliferation, production of IL-2 and up-regulation of the IL-2 receptor. The 120-kD **CD30** surface antigen belongs to the tumour necrosis factor (TNF) receptor superfamily. It is expressed by activated T helper (Th) cells and its expression is sustained in Th2 cells. We have analysed the effect of GSH and NAC on the cytokine profile and **CD30** expression on human allergen-specific T cell clones (TCC). TCC were stimulated with anti-CD3 antibodies in the presence of different concentrations of GSH and NAC. Both thiols caused a dose dependent down-regulation of IL-4, IL-5 and IFN-gamma levels in Th0 and Th2 clones, with the most pronounced decrease of IL-4. Furthermore, they down-regulated the surface expression of **CD30**, and the levels of soluble **CD30** (sCD30) in the culture supernatants were decreased. In contrast, the surface expression of CD28 or **CD40 ligand** (**CD40L**) was not significantly changed after treatment with 20 mM NAC. These results indicate that GSH and NAC favour a Th1 response by a preferential down-regulation of IL-4. In addition, the expression of **CD30** was down regulated by GSH and NAC, suggesting that **CD30** expression is dependent on IL-4, or modified by NAC. In the likely event that **CD30** and its soluble counterpart prove to contribute to the pathogenesis in Th2 related diseases such as allergy, NAC may be

considered as a future therapeutic agent in the treatment of these diseases.

4/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

12615531 BIOSIS NO.: 200000369033
TTRAP, a novel protein that associates with CD40, **tumor** necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that **inhibits** nuclear factor-kappaB activation.
AUTHOR: Pype Stefan; Declercq Wim; Ibrahimi Abdelilah; Michiels Christine; Van Rietschoten Johanna G I; Dewulf Nathalie; de Boer Mark; Vandenabeele Peter; Huylebroeck Danny(a); Remacle Jacques E
AUTHOR ADDRESS: (a)Department of Cell Growth, Differentiation and Development, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Herestraat 49, Campus Gasthuisberg, B-3000, Leuven **Belgium
JOURNAL: Journal of Biological Chemistry 275 (24):p18586-18593 June 16, 2000
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: CD40 belongs to the tumor necrosis factor (TNF) receptor family. CD40 signaling involves the recruitment of TNF receptor-associated factors (TRAFs) to its cytoplasmic domain. We have identified a novel intracellular CD40-binding protein termed TRAF and TNF receptor-associated protein (TTRAP) that also interacts with TNF-R75 and **CD30**. The region of the CD40 cytoplasmic domain that is required for TTRAP association overlaps with the TRAF6 recognition motif. Association of TTRAP with CD40 increases profoundly in response to treatment of cells with **CD40L**. Interestingly, TTRAP also associates with TRAFs, with the highest affinity for TRAF6. In transfected cells, TTRAP inhibits in a dose- dependent manner the transcriptional activation of a nuclear factor-kappaB (NF-kappaB)-dependent reporter mediated by CD40, TNF-R75 or Phorbol 12-myristate 13-acetate (PMA) and to a lesser extent by TRAF2, TRAF6, TNF-alpha, or interleukin-1beta (IL-1beta). TTRAP does not affect stimulation of NF-kappaB induced by overexpression of the NF-kappaB-inducing kinase (NIK), the IkappaB kinase alpha (IKKalpha), or the NF-kappaB subunit P65/RelA, suggesting it acts upstream of the latter proteins. Our results indicate that we have isolated a novel regulatory factor that is involved in signal transduction by distinct members of the TNF receptor family.

4/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

11525042 BIOSIS NO.: 199800306374
Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (**CD40 ligand**) costimulatory molecules in tumor cells.
AUTHOR: Couderc Bettina; Zitvogel Laurence; Douin-Echinard Victorine; Djennane Leila; Tahara Hideaki; Favre Gilles; Lotze Michael T; Robbins Paul D(a)
AUTHOR ADDRESS: (a)Dep. Mol. Genet. and Biochem., W1246 Biomed. Sci. Tower, Univ. Pittsburgh Sch. Med., Pittsburgh,**USA
JOURNAL: Cancer Gene Therapy 5 (3):p163-175 May-June, 1998
ISSN: 0929-1903

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: CD70 (CD27 ligand (CD27L)), CD153 (**CD30L**), and CD154 (**CD40L**) are members of the tumor necrosis factor family of costimulatory molecules and expressed on the surface of T cells that are important for both T- and B-cell help. We examined the capacity for expression of these tumor necrosis factor family members on tumor cells to induce an antitumor response either in the presence or absence of interleukin 12. Retroviral vectors were constructed that expressed high levels of membrane bound CD70, CD153, or CD154 following infection and selection of the murine tumor lines MCA 207 or TS/A. The genetically modified tumor cells expressing these molecules were able to stimulate splenic cell proliferation, demonstrating that the expressed costimulatory molecules were biologically active. When tested for tumor establishment, the expression of either CD70 or CD154 was able to slow **tumor** growth. Similarly, CD70 or CD154 were able to induce antitumor immunity at a higher frequency when tested in vaccination and **therapy** models. CD70 was able to induce antitumor immunity at a level similar to CD80 when tested either in the presence or absence of interleukin 12. Moreover, coexpression of CD70 and CD80 was able to synergize the induction of a higher frequency of antitumor immunity in a vaccination model. Taken together, our results suggest that CD154 and in particular CD70 are able to contribute to the induction of the immune response to tumor in murine models and thus may be of use for human clinical trials.

4/7/7 (Item 7 from file: 5)

11226541 BIOSIS NO.: 199800007873
CD30 ligand in lymphoma patients with **CD30**!+ tumors.
AUTHOR: Younes Anas(a); Consoli Ugo; Snell Virginia; Clodi Katharina; Kliche Kay-Oliver; Palmer J Lynn; Gruss Hans J; Armitage Richard; Thomas Elaine K; Cabanillas Fernando; Andreeff Michael
AUTHOR ADDRESS: (a)Dep. Hematol., Section Lymphoma, Univ. Texas M.D. Anderson Cancer Cent., 1515 Holcombe Blvd., Ho**USA
JOURNAL: Journal of Clinical Oncology 15 (11):p3355-3362 Nov., 1997
ISSN: 0732-183X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Purpose: **CD30** ligand (**CD30L**), which is expressed on resting B and activated T lymphocytes, can induce cell death in several **CD30**!+ cell lines. Patients with **CD30**!+ tumors (Hodgkin's disease and Ki-1!+ non-Hodgkin's lymphoma) frequently have elevated soluble **CD30** (sCD30) levels in their serum, which correlates with a poor prognosis. The role of sCD30 in protecting tumor cells from **CD30L**-mediated cell death and the pattern of **CD30L** expression on human peripheral-blood lymphocytes (PBLs) of normal donors and patients with **CD30**!+ tumors are investigated. Materials and Methods: **CD30L** surface protein expression was determined by two-color flow cytometry on PBLs of patients with **CD30**!+ tumors and normal individuals. **CD30L** levels were determined on subsets of PBLs before and after stimulation with phytohemagglutinin (PHA), anti-CD3 antibody, or **CD40L**. sCD30 was measured by enzyme-linked immunosorbent assay (ELISA). The apoptotic activity of membrane-bound **CD30L** was tested in a **CD30**!+ cell line by the annexin V-binding method. Results: Unstimulated T lymphocytes of normal donors and patients with lymphoma rarely expressed **CD30L** surface protein,

but were able to express it after stimulation with PHA or anti-CD3 antibody. Resting B cells of patients with **CD30**!+ tumors had lower levels of detectable surface **CD30L** compared with normal donors (mean, 55% and 80.6%, respectively; P = .0008). Patients with high levels of serum sCD30 had lower detectable levels of **CD30L** on their PBLs (R!2 = .72, P = .0008) and exogenous sCD30 **blocked** membrane-bound **CD30L**-mediated apoptosis in a **CD30**!+ cell line. Conclusion: In patients with **CD30**!+ **tumors**, sCD30 can decrease the availability of **CD30L** on PBLs. **Blocking** the apoptosis-inducing activity of **CD30L** by its soluble receptor may explain how **CD30**!+ **tumors** escape immunosurveillance and may be related to the reported poor prognosis of patients who have elevated sCD30 levels.

4/7/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11933828 EMBASE No: 2003044479
T-cell costimulatory pathways relevant to transplant rejection and tolerance
Wells A.D.
Dr. A.D. Wells, Dept. of Pathology/Laboratory Med., Children's Hospital of Philadelphia, University of Pennsylvania, 3516 Civic Center Blvd., Philadelphia, PA 19104-4318 United States
Transplantation Reviews (TRANSPL. REV.) (United States) 2002, 16/4 (205-219)
ISSN: 0955-470X
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 214

4/7/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11449616 EMBASE No: 2002021386
Expression of **CD40 ligand** (CD154) in B and T lymphocytes of Hodgkin disease: Potential therapeutic significance
Clodi K.; Asgari Z.; Younes M.; Palmer J.L.; Cabanillas F.; Carbone A.; Andreeff M.; Younes A.
Dr. A. Younes, Department of Lymphoma/Myeloma, University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 United States
AUTHOR EMAIL: ayounes@notes.mdacc.tmc.edu
Cancer (CANCER) (United States) 01 JAN 2002, 94/1 (1-5)
CODEN: CANCA ISSN: 0008-543X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 20

BACKGROUND. The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express **CD30** and CD40 receptors that can activate nuclear factor kappa B and transduce survival signals. The authors have reported previously that the B lymphocytes of HD express **CD30** ligand (**CD30L**, CD153). Furthermore, they and others have reported previously that the **CD40L** survival pathway is augmented in patients with B-cell malignancies, as **CD40L** was constitutively expressed by the malignant B cells and infiltrating T cells, and sera from those patients contained elevated levels of soluble **CD40L**. In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented **CD40L** signals in HD patients.

METHODS. The expression of **CD40L** on lymphocyte subsets of patients with classic HD was determined by two-color fluorescent-activated cell sorter analysis. Serum soluble **CD40L** levels were determined by enzyme linked immunosorbent assay. RESULTS. **CD40L** was constitutively expressed on both the T and B cells of HD patients but was more prominently expressed on the B lymphocytes. Soluble **CD40L** was detected in the serum of 17 of 37 patients (45%) and was higher than 1 ng/mL in 4 patients (10%). Both interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS cells and surrounding T cells, up-regulated **CD40L** expression on normal B cells. CONCLUSIONS. Thus, the expression of **CD40L** and **CD30L** on the B cells of HD patients suggests that B lymphocytes may play a role in the regulation of H/RS cell growth in vivo. Depriving H/RS cells from **CD30L** and **CD40L** survival signals by eliminating B cells from HD lesions may be of **therapeutic** value. (c) 2002 American **Cancer** Society.

4/7/10 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

07928709 EMBASE No: 1999402580
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells
Kashii Y.; Giorda R.; Herberman R.B.; Whiteside T.L.; Vujanovic N.L.
Dr. N.L. Vujanovic, University of Pittsburgh, Cancer Institute, Biomedical Science Tower W1045, 211 Lothrop Street, Pittsburgh, PA 15213 United States
AUTHOR EMAIL: vujanovicn1@msx.upmc.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 NOV 1999, 163/10 (5358-5366)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 37

Natural killer cells mediate spontaneously secretory/necrotic killing against rare leukemia cell lines and a nonsecretory/apoptotic killing against a large variety of tumor cell lines. The molecules involved in nonsecretory/apoptotic killing are largely undefined. In the present study, freshly isolated, nonactivated, human NK cells were shown to express TNF, lymphotoxin (LT)-alpha, LT-beta, Fas ligand (L), CD27L, **CD30L**, OX40L, 4-1BBL, and TNF-related apoptosis-inducing ligand (TRAIL), but not **CD40L** or nerve growth factor. Complementary receptors were demonstrated to be expressed on the cell surface of solid tumor cell lines susceptible to apoptotic killing mediated by NK cells. Individually applied, antagonists of TNF, LT-alphainf 1Binf 2, or FasL fully **inhibited** NK cell-mediated apoptotic killing of **tumor** cells. On the other hand, recombinant TNF, LT-alphainf 1Binf 2, or FasL applied individually or as pairs were not cytotoxic. In contrast, a mixture of the three ligands mediated significant apoptosis in tumor cells. These findings demonstrate that human NK cells constitutively express several of the TNF family ligands and induce apoptosis in tumor cells by simultaneous engagement of at least three of these cytotoxic molecules.

```
? t s4/kwic/24,25
>>>KWIC option is not available in file(s): 399
? ds

Set     Items   Description
S1        745   (CD40L OR CD40(W)LIGAND) AND (TREAT? OR THERAP? OR PREVENT?
                OR SUPPRESS? OR BLOCK? OR INHIBIT?)(20N)(CANCER? OR TUMOR? OR
                TUMOUR?)
S2          1   S1 AND PHOTODYNAMIC
S3         33   S1 AND CD30?
```

S4 25 RD S3 (unique items)
?